Saturday, June 18, 2011
Treatment of Osteoarthritis
Treatment of osteoarthritis and hypertension in a patient
Osteoarthritis and hypertension (also be familiar with as hypertension) are very general among the elderly in the United States, the United Kingdom and Canada. As people age, the chances of osteoarthritis increase the risk of cardiovascular complaint. Consequently a substantial number of patients with osteoarthritis is likely to develop hypertension at a later stage.
The anti-inflammatory drug used to treat osteoarthritis may raise blood pressure. Health care costs could be keep away fromed and there will be less risk of cardiovascular complaint, if control of blood pressure is not destabilized among hypertensive patients taking cyclo-oxygenase-2 (COX-2) inhibitors specific (non-steroidal anti-inflammatory drugs) used for the treatment of osteoarthritis. Data from the Third National Health and Nutrition Examination Survey (NHANES III) provided the distribution of developing cardiovascular risk factors among U.S. adults with osteoarthritis and hypertension. The model of cardiovascular complaint life expectancy was used to estimate the impact of an increase of 2.26 percent of the systolic blood pressure based on the results of randomized trails comparing COX-2 specific inhibitors.
A similar analysis was conducted for American adults with osteoarthritis and untreated hypertension (> or = 140/90 mm Hg). If 7.3 million American people were treated for hypertension, and they would keep their blood pressure, it would keep away from> 30,000 stroke deaths and 2,000 deaths from ischemic heart complaint resulting in years of individuals> 449,000 of life saved and 1.4 billion dollars of savings in direct costs of health care. When 3.8 million Americans with untreated hypertension are considered, maintaining blood pressure would prevent> 47 000 stroke deaths, 39,000 deaths from ischemic heart complaint, and this would result in 668,000 people years of life saved and> 2.4 billion recorded in direct costs of health care.